Sep 07, 2023 / 12:50PM GMT
Samantha Lynn Semenkow - Citigroup Inc., Research Division - VP
All right. Hello, everyone. Thank you for being here this morning. It's my pleasure to introduce John Evans, CEO of Beam Therapeutics. John, thank you for being here.
John M. Evans - Beam Therapeutics Inc. - CEO & Director
It's great to be here. Thanks for having me.
Samantha Lynn Semenkow - Citigroup Inc., Research Division - VP
Excellent. So maybe we could just start with some opening remarks, 2 to 3 minutes of overview of Beam for those that are maybe less familiar.
John M. Evans - Beam Therapeutics Inc. - CEO & Director
Sure. So Beam is a next-generation gene editing company. We were founded around a technology called base editing. So base editing is a new form of CRISPR. So we're using CRISPR for the same ability to target the genome selectively using programmable, guide RNA driven targeting, which we think is an incredible breakthrough in the field, but we're not using it to do the edit. We don't
Beam Therapeutics Inc at Citi BioPharma Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers